Management of mucormycosis coexisting with aspergillosis in pediatric age group – a case report

[1]  W. Steinbach.  Latest Thoughts on Treating Pediatric Mucormycosis. , 2020, Journal of the Pediatric Infectious Diseases Society.

[2]  S. Filler,et al.  Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. , 2016, The Journal of clinical investigation.

[3]  N. Srivastava,et al.  Palatal Mucormycosis in An Infant. , 2015, Journal of dentistry for children.

[4]  D. Galarza-Delgado,et al.  Clinical Features and Outcome of Mucormycosis , 2014, Interdisciplinary perspectives on infectious diseases.

[5]  Shunying Zhao,et al.  [Risk factors of invasive fungal infections in patients admitted to non- hematological oncology department and pediatric intensive care unit]. , 2013, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[6]  T. Walsh,et al.  Rhino-Orbital-Cerebral Mucormycosis , 2012, Current Infectious Disease Reports.

[7]  A. Attarbaschi,et al.  Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases , 2011, Mycoses.

[8]  S. Filler,et al.  The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. , 2010, The Journal of clinical investigation.

[9]  M. Maris,et al.  Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. , 2003, Blood.

[10]  J. Shenep,et al.  Aspergillosis in children with cancer: A 34-year experience. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A. Coetzee,et al.  Mucormycosis. Case report and review. , 1974, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.